相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
1
100.0%
暂无批准数据
- Product development partnerships have delivered more than 79 novel health tools to 2.4 billion people over nearly 30 years, prioritizing public health over market returns. - PDPs address diseases neglected by traditional pharmaceutical development, including malaria, sleeping sickness, neonatal infections, and drug-resistant bacterial infections. - Landmark PDP achievements include acoziborole for sleeping sickness, Coartem Baby for infant malaria, and zoliflodacin for drug-resistant gonorrhea. - As global health reform advances, experts argue that innovation mechanisms like PDPs must remain central to a country-led system that serves underserved populations.
- The BARNARDS II study across Pakistan, Bangladesh, and Nigeria found WHO-recommended first-line antibiotics ampicillin plus gentamicin were effective against only 25% of neonatal sepsis pathogens. - High levels of antimicrobial resistance in low- and middle-income countries make identifying effective empirical antibiotic regimens extremely challenging for treating newborn infections. - The NeoSep1 trial is expanding to seven new countries across Africa and Asia to identify safer and more effective antibiotic combinations for neonatal sepsis treatment. - Researchers emphasize the need for locally informed treatment strategies rather than global one-size-fits-all approaches to address varying resistance patterns.
